The Gene, the New Drugs, and the Blood Test Changing How Alzheimer's Gets Caught Early

Dementia is the pillar in this series with the least mature single risk score, we've been upfront about that throughout. But it's also the pillar where the underlying science has moved the fastest in the past few years, on genetics, on treatment, and on early detection. This post covers all three.

The gene: ApoE4

ApoE4 is a variant of a gene involved in how the body processes fats and repairs brain tissue. Carrying one copy raises Alzheimer's risk meaningfully, and carrying two copies, one from each parent, raises it substantially further. It's increasingly testable, some direct-to-consumer genetic services include it, and it's become a common topic in longevity and brain health discussions for exactly that reason. It's worth being clear about what it does and doesn't tell you, carrying ApoE4 raises risk, it does not guarantee developing Alzheimer's, and plenty of carriers never do. It's a risk factor to know, not a diagnosis to fear.

The new drugs, and an honest look at what they actually deliver

Lecanemab and donanemab represent a real category shift, they're the first drugs shown to actually clear amyloid plaque from the brain and produce a statistically significant slowing of cognitive decline in clinical trials, rather than just managing symptoms the way older Alzheimer's medications did.

Here's the part worth sitting with rather than glossing over. A large 2026 Cochrane review pooling 17 trials and over 20,000 participants across this entire drug class found that, on average, the real-world cognitive and functional benefit at around 18 months was small, small enough that reviewers questioned whether it was clinically meaningful for the average patient, while the risk of brain swelling and bleeding, a known side effect of this drug class, was real and not trivial. That doesn't mean these drugs are worthless, the original pivotal trials did show statistically real slowing of decline, and some patients likely benefit more than the population average suggests. But it does mean the honest picture is genuinely mixed, not the clean breakthrough narrative that sometimes gets attached to it in the press.

The blood test that's changing early detection

This is arguably the most practically useful development of the three. A protein called p-tau217, measurable from a simple blood draw, has emerged as a strong marker of the underlying brain changes associated with Alzheimer's, and it performs close to far more invasive and expensive testing like PET brain imaging. A large 2026 Swedish study presented at the Alzheimer's Association International Conference found that using a validated p-tau217 blood test raised diagnostic accuracy substantially in both secondary and primary care settings, moving primary care physicians' diagnostic accuracy from roughly two-thirds correct to over 90%. Several versions of this test have now received formal clearance, and it's becoming realistic for a blood draw, not just a specialist referral, to flag Alzheimer's-related changes early. It isn't part of a routine panel, see which blood test to actually get for what a standard draw does and doesn't cover.

What this means practically

If dementia runs in your family, particularly with early onset, ApoE4 testing is a reasonable conversation to have with a genetic counselor, alongside the understanding that a positive result is a risk signal, not a sentence. If you or someone you love is showing early cognitive changes, ask specifically whether a p-tau217 blood test is available and appropriate, since it's a meaningfully lower-friction path to clarity than it used to be. And if amyloid-clearing drug treatment comes up as an option, this is exactly the kind of decision worth asking your doctor to walk through the real magnitude of expected benefit versus real risk for your specific situation, not just whether the drug is available.